HRP20040502A2 - Catheter composition and uses thereof - Google Patents

Catheter composition and uses thereof

Info

Publication number: HRP20040502A2
Authority: HR; Croatia
Prior art keywords: catheter; plasminogen activator; preparation; package; effective amount
Prior art date: 2001-11-26

Application number

Other languages

English (en)

Croatian (hr)

Inventor

Charles P Semba

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-26

Filing date

2004-06-04

Publication date

2004-12-31

2004-06-04 Application filed by Genentech Inc filed Critical Genentech Inc

2004-12-31 Publication of HRP20040502A2 publication Critical patent/HRP20040502A2/hr

Links

239000000203 mixture Substances 0.000 title claims description 32
238000000034 method Methods 0.000 claims description 75
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 60
238000002360 preparation method Methods 0.000 claims description 53
239000000243 solution Substances 0.000 claims description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 42
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 42
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
102000009123 Fibrin Human genes 0.000 claims description 28
108010073385 Fibrin Proteins 0.000 claims description 28
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 28
102000001938 Plasminogen Activators Human genes 0.000 claims description 28
108010001014 Plasminogen Activators Proteins 0.000 claims description 28
229950003499 fibrin Drugs 0.000 claims description 28
229940127126 plasminogen activator Drugs 0.000 claims description 28
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 23
239000003755 preservative agent Substances 0.000 claims description 23
208000007536 Thrombosis Diseases 0.000 claims description 21
235000019445 benzyl alcohol Nutrition 0.000 claims description 20
230000002335 preservative effect Effects 0.000 claims description 20
238000002347 injection Methods 0.000 claims description 19
239000007924 injection Substances 0.000 claims description 19
108010039185 Tenecteplase Proteins 0.000 claims description 18
229960000216 tenecteplase Drugs 0.000 claims description 18
239000002738 chelating agent Substances 0.000 claims description 16
230000003385 bacteriostatic effect Effects 0.000 claims description 14
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 13
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
229960005356 urokinase Drugs 0.000 claims description 12
102000008946 Fibrinogen Human genes 0.000 claims description 11
108010049003 Fibrinogen Proteins 0.000 claims description 11
229940012952 fibrinogen Drugs 0.000 claims description 11
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 7
238000002156 mixing Methods 0.000 claims description 5
108010051412 reteplase Proteins 0.000 claims description 5
239000008215 water for injection Substances 0.000 claims description 5
229960002917 reteplase Drugs 0.000 claims description 4
229960000187 tissue plasminogen activator Drugs 0.000 claims description 4
108050006955 Tissue-type plasminogen activator Proteins 0.000 claims 5
102100033571 Tissue-type plasminogen activator Human genes 0.000 claims 5
238000012360 testing method Methods 0.000 description 83
239000000523 sample Substances 0.000 description 63
230000000845 anti-microbial effect Effects 0.000 description 33
230000009467 reduction Effects 0.000 description 28
230000009089 cytolysis Effects 0.000 description 27
238000002835 absorbance Methods 0.000 description 23
229960003318 alteplase Drugs 0.000 description 22
208000015181 infectious disease Diseases 0.000 description 20
235000018102 proteins Nutrition 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 20
108090000623 proteins and genes Proteins 0.000 description 20
230000000694 effects Effects 0.000 description 18
239000000463 material Substances 0.000 description 18
239000003146 anticoagulant agent Substances 0.000 description 16
239000004599 antimicrobial Substances 0.000 description 16
229940099983 activase Drugs 0.000 description 15
239000012895 dilution Substances 0.000 description 15
238000010790 dilution Methods 0.000 description 15
238000011010 flushing procedure Methods 0.000 description 15
102000013566 Plasminogen Human genes 0.000 description 12
108010051456 Plasminogen Proteins 0.000 description 12
239000003085 diluting agent Substances 0.000 description 12
229920000669 heparin Polymers 0.000 description 12
230000002906 microbiologic effect Effects 0.000 description 12
229960005486 vaccine Drugs 0.000 description 12
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
229960002897 heparin Drugs 0.000 description 11
241000894006 Bacteria Species 0.000 description 10
238000011534 incubation Methods 0.000 description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
229940127219 anticoagulant drug Drugs 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
230000002792 vascular Effects 0.000 description 9
238000005119 centrifugation Methods 0.000 description 8
230000008859 change Effects 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000011521 glass Substances 0.000 description 8
238000001631 haemodialysis Methods 0.000 description 8
230000000322 hemodialysis Effects 0.000 description 8
244000005700 microbiome Species 0.000 description 8
229940012957 plasmin Drugs 0.000 description 8
239000012898 sample dilution Substances 0.000 description 8
239000011248 coating agent Substances 0.000 description 7
238000000576 coating method Methods 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003527 fibrinolytic agent Substances 0.000 description 7
230000003480 fibrinolytic effect Effects 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
239000002609 medium Substances 0.000 description 7
239000002245 particle Substances 0.000 description 7
239000012460 protein solution Substances 0.000 description 7
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 6
241000233866 Fungi Species 0.000 description 6
108090000190 Thrombin Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
239000000645 desinfectant Substances 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
229960004023 minocycline Drugs 0.000 description 6
239000013642 negative control Substances 0.000 description 6
239000012086 standard solution Substances 0.000 description 6
239000008223 sterile water Substances 0.000 description 6
229960004072 thrombin Drugs 0.000 description 6
229920001817 Agar Polymers 0.000 description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
239000004793 Polystyrene Substances 0.000 description 5
239000008272 agar Substances 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000012470 diluted sample Substances 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
238000011081 inoculation Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
229920001296 polysiloxane Polymers 0.000 description 5
229920000136 polysorbate Polymers 0.000 description 5
229920002223 polystyrene Polymers 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
241000222120 Candida <Saccharomycetales> Species 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
229960005475 antiinfective agent Drugs 0.000 description 4
239000012131 assay buffer Substances 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000012417 linear regression Methods 0.000 description 4
238000004811 liquid chromatography Methods 0.000 description 4
239000000178 monomer Substances 0.000 description 4
239000012925 reference material Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
241000191940 Staphylococcus Species 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002785 anti-thrombosis Effects 0.000 description 3
229960004676 antithrombotic agent Drugs 0.000 description 3
230000000721 bacterilogical effect Effects 0.000 description 3
239000008228 bacteriostatic water for injection Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
229960003260 chlorhexidine Drugs 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
229950007919 egtazic acid Drugs 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
229950008882 polysorbate Drugs 0.000 description 3
229920002635 polyurethane Polymers 0.000 description 3
239000004814 polyurethane Substances 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
239000008227 sterile water for injection Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
230000002485 urinary effect Effects 0.000 description 3
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
229940123150 Chelating agent Drugs 0.000 description 2
241000721047 Danaus plexippus Species 0.000 description 2
206010064687 Device related infection Diseases 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
108010015899 Glycopeptides Proteins 0.000 description 2
102000002068 Glycopeptides Human genes 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108010031891 KHRR 296-299 AAAA T103N Proteins 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
229940127090 anticoagulant agent Drugs 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
239000001354 calcium citrate Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000020832 chronic kidney disease Diseases 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000013480 data collection Methods 0.000 description 2
230000008021 deposition Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
208000028208 end stage renal disease Diseases 0.000 description 2
201000000523 end stage renal failure Diseases 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000009434 installation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
235000019799 monosodium phosphate Nutrition 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000012488 sample solution Substances 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
229960003600 silver sulfadiazine Drugs 0.000 description 2
UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
235000011008 sodium phosphates Nutrition 0.000 description 2
ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
229960004267 taurolidine Drugs 0.000 description 2
AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 2
229960000103 thrombolytic agent Drugs 0.000 description 2
235000021476 total parenteral nutrition Nutrition 0.000 description 2
235000013337 tricalcium citrate Nutrition 0.000 description 2
229960003500 triclosan Drugs 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
239000006150 trypticase soy agar Substances 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 description 1
FFRVQTGCNAGNJO-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-pyrrolidin-1-ylethanamine Chemical compound C=1C=C(F)C=CC=1C(CN)N1CCCC1 FFRVQTGCNAGNJO-UHFFFAOYSA-N 0.000 description 1
MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical compound NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 description 1
KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
208000032840 Catheter-Related Infections Diseases 0.000 description 1
230000010736 Chelating Activity Effects 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
101100369915 Drosophila melanogaster stas gene Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002306 Glycocalyx Polymers 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
238000013494 PH determination Methods 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
206010062546 Thrombosis in device Diseases 0.000 description 1
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000000941 anti-staphylcoccal effect Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229960003093 antiseptics and disinfectants Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
235000011188 calcium disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000013522 chelant Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960000958 deferoxamine Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
229960001051 dimercaprol Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
229940009626 etidronate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
230000002615 fibrolytic effect Effects 0.000 description 1
239000012537 formulation buffer Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
210000004517 glycocalyx Anatomy 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
231100000663 medical toxicology Toxicity 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000012009 microbiological test Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000003058 plasma substitute Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
238000007747 plating Methods 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229940116243 retavase Drugs 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229960005346 succimer Drugs 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
238000011003 system suitability test Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229950007343 taurultam Drugs 0.000 description 1
229940072172 tetracycline antibiotic Drugs 0.000 description 1
229960003766 thrombin (human) Drugs 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
210000002620 vena cava superior Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000004246 zinc acetate Substances 0.000 description 1
229960000314 zinc acetate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Detergent Compositions (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)

HRP20040502 2001-11-26 2004-06-04 Catheter composition and uses thereof HRP20040502A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33336901P	2001-11-26	2001-11-26
PCT/US2002/037878 WO2003045466A2 (en)	2001-11-26	2002-11-25	Catheter composition and uses thereof

Publications (1)

Publication Number	Publication Date
HRP20040502A2 true HRP20040502A2 (en)	2004-12-31

Family

ID=23302492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20040502 HRP20040502A2 (en)	2001-11-26	2004-06-04	Catheter composition and uses thereof

Country Status (28)

Country	Link
US (3)	US20030206906A1 (xx)
EP (1)	EP1455858A4 (xx)
JP (1)	JP4458240B2 (xx)
KR (2)	KR20100102745A (xx)
CN (1)	CN100478027C (xx)
AR (1)	AR037437A1 (xx)
AU (2)	AU2002365408B2 (xx)
BR (1)	BR0215098A (xx)
CA (1)	CA2467645C (xx)
CO (1)	CO5580795A2 (xx)
EA (1)	EA007594B1 (xx)
EC (2)	ECSDI045123S (xx)
HR (1)	HRP20040502A2 (xx)
HU (1)	HUP0600436A3 (xx)
IL (2)	IL162083A0 (xx)
IS (1)	IS7275A (xx)
ME (1)	ME00015B (xx)
MX (1)	MXPA04004948A (xx)
MY (1)	MY140404A (xx)
NO (1)	NO331700B1 (xx)
NZ (1)	NZ533029A (xx)
PL (1)	PL371760A1 (xx)
RS (1)	RS46204A (xx)
TW (1)	TWI262794B (xx)
UA (1)	UA81235C2 (xx)
UY (1)	UY27550A1 (xx)
WO (1)	WO2003045466A2 (xx)
ZA (1)	ZA200404024B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002365408B2 (en) *	2001-11-26	2008-04-24	Genentech, Inc.	Catheter composition and uses thereof
US7128923B2 (en) *	2003-03-31	2006-10-31	Procyte Corporation	Preserved and stable compositions containing peptide copper complexes and method related thereto
WO2008027000A2 (en) *	2006-08-28	2008-03-06	Omnio Healer Ab	Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
AU2007290881B2 (en) *	2006-08-28	2013-03-07	Omnio Healer Ab	Candidates against infection
US8916148B2 (en)	2006-11-07	2014-12-23	Genentech, Inc.	Tissue plasminogen activator variant uses
EP2160152B1 (en)	2007-06-01	2016-07-27	Arrow International, Inc.	Combined fibrinolytic and antimicrobial catheter and uses thereof
JP2010538092A (ja) *	2007-09-07	2010-12-09	ユナイテッドセラピューティクスコーポレーション	グラム陰性菌に対して選択的殺菌活性を有するバッファー溶液およびそれを使用する方法
US8545459B2 (en) *	2009-02-25	2013-10-01	Teleflex Medical Incorporated	Stabilized enzyme compositions
US9333280B2 (en)	2009-02-25	2016-05-10	Teleflex Medical Incorporated	Stabilized enzyme compositions
US20110213025A1 (en) *	2009-08-10	2011-09-01	Proviflo, Llc	Catheter Lock Solutions Utilizing Tocopherol and Mid-Chain Fatty Acids
CN103083726A (zh) *	2013-03-04	2013-05-08	昆明市第一人民医院	一种肝脏组织脱细胞液
US10456570B2 (en)	2015-06-11	2019-10-29	Proviflo, Llc	Graft-port hemodialysis systems, devices, and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI831484L (fi) *	1982-05-05	1983-11-06	Genentech Inc	Plasminogen aktivator foer maenskovaevnad
US5000185A (en) *	1986-02-28	1991-03-19	Cardiovascular Imaging Systems, Inc.	Method for intravascular two-dimensional ultrasonography and recanalization
US5019096A (en) *	1988-02-11	1991-05-28	Trustees Of Columbia University In The City Of New York	Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5270198A (en) *	1988-05-20	1993-12-14	Genentech, Inc.	DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8820945D0 (en) *	1988-09-07	1988-10-05	Smith & Nephew	Medical articles
FR2661790B1 (fr) *	1990-05-03	1995-08-25	France Etat	Dispositif d'amplification tres large bande continu-hyperfrequences, notamment realisable en circuit integre.
WO1991017724A1 (en) *	1990-05-17	1991-11-28	Harbor Medical Devices, Inc.	Medical device polymer
US5399158A (en) *	1990-05-31	1995-03-21	The United States Of America As Represented By The Secretary Of The Army	Method of lysing thrombi
US5363754A (en) *	1991-09-03	1994-11-15	Grainco Queensland Co-Operative Association Limited	Apparatus for preparing animal feedstuff from cotton seed
JPH05291891A (ja) *	1992-02-14	1993-11-05	Ricoh Co Ltd	一次乱数パルス列発生回路装置
ES2107041T3 (es) *	1992-06-03	1997-11-16	Genentech Inc	Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
US5688516A (en) *	1992-11-12	1997-11-18	Board Of Regents, The University Of Texas System	Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) *	1992-11-12	1994-11-08	Univ. Of Tx Md Anderson Cancer Center	M-EDTA pharmaceutical preparations and uses thereof
US5849736A (en) *	1993-11-24	1998-12-15	The Dupont Merck Pharmaceutical Company	Isoxazoline and isoxazole fibrinogen receptor antagonists
DE69426604T2 (de)	1993-11-24	2001-05-10	Dupont Pharmaceuticals Co., Wilmington	Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten
US5885967A (en) *	1994-03-04	1999-03-23	Eli Lilly And Company	Antithrombotic agents
US5509896A (en) *	1994-09-09	1996-04-23	Coraje, Inc.	Enhancement of thrombolysis with external ultrasound
CA2178541C (en) *	1995-06-07	2009-11-24	Neal E. Fearnot	Implantable medical device
US5772640A (en) *	1996-01-05	1998-06-30	The Trustees Of Columbia University Of The City Of New York	Triclosan-containing medical devices
US5932299A (en) *	1996-04-23	1999-08-03	Katoot; Mohammad W.	Method for modifying the surface of an object
US5840733A (en) *	1996-07-01	1998-11-24	Redcell, Canada, Inc.	Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5837688A (en) *	1996-11-27	1998-11-17	Gelfand; Mathew I.	Use of thrombolytic reagents for prevention of vascular disease
WO1998028326A1 (en)	1996-12-23	1998-07-02	Biochem Pharma Inc.	Bicyclic thrombin inhibitors
GB9626795D0 (en) *	1996-12-23	1997-02-12	Geistlich Soehne Ag	Combating infection in delivery systems
US5981826A (en) *	1997-05-05	1999-11-09	Georgia Tech Research Corporation	Poly(vinyl alcohol) cryogel
JPH10328293A (ja)	1997-06-04	1998-12-15	Unitika Ltd	医療用具及びその製造方法
US6206914B1 (en) *	1998-04-30	2001-03-27	Medtronic, Inc.	Implantable system with drug-eluting cells for on-demand local drug delivery
US6166007A (en) *	1998-07-02	2000-12-26	Sodemann; Klaus	Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
US6174537B1 (en) *	1998-09-25	2001-01-16	Becton, Dickinson And Company	Catheter flush solution and method for its use
CA2364252A1 (en) *	1999-03-11	2000-09-14	Bristol-Myers Squibb Pharma Company	Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
BR0010381A (pt)	1999-03-11	2002-02-05	Du Pont Pharm Co	Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
CA2302720C (en)	1999-03-29	2009-07-14	Ed Geistlich Sohne Ag Fur Chemische Industrie	Anticoagulant/sterilizing compositions and methods
US6187768B1 (en) *	1999-06-01	2001-02-13	Becton, Dickinson And Company	Kit for flushing medical devices and method of preparation
EP1060747A3 (en) *	1999-06-16	2001-12-05	New York Blood Center, Inc.	Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
US6592564B2 (en) *	1999-07-23	2003-07-15	Vasca, Inc.	Methods and kits for locking and disinfecting implanted catheters
US6350251B1 (en) *	2000-01-18	2002-02-26	Biolink Corporation	Biocidal locks
US20010031981A1 (en) *	2000-03-31	2001-10-18	Evans Michael A.	Method and device for locating guidewire and treating chronic total occlusions
PT1284780E (pt)	2000-05-10	2008-08-18	Ash Access Technology Inc	Uma solução de controlo de cateter incluindo um fotooxidante
US6772640B1 (en) *	2000-10-10	2004-08-10	Mks Instruments, Inc.	Multi-temperature heater for use with pressure transducers
US20050215978A1 (en) *	2001-05-25	2005-09-29	Ash Stephen R	Method of enhancing catheter patency using a citrate salt catheter lock solution
AU2002365408B2 (en) *	2001-11-26	2008-04-24	Genentech, Inc.	Catheter composition and uses thereof
US20070014779A1 (en) *	2002-11-14	2007-01-18	Genentech, Inc.	Plasminogen activator variant formulations
ATE354380T1 (de)	2003-02-03	2007-03-15	Polaschegg Hans-Dietrich Dr Te	Zusammensetzung zur prävention von infektionen durch subkutane prothesen
US7696182B2 (en)	2004-11-02	2010-04-13	Nd Partners, Llc	Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US7749529B2 (en)	2005-02-08	2010-07-06	Ash Access Technology, Inc.	Catheter lock solution comprising citrate and a paraben
US8916148B2 (en)	2006-11-07	2014-12-23	Genentech, Inc.	Tissue plasminogen activator variant uses

2002
- 2002-11-25 AU AU2002365408A patent/AU2002365408B2/en not_active Ceased
- 2002-11-25 UA UA20040605026A patent/UA81235C2/uk unknown
- 2002-11-25 MX MXPA04004948A patent/MXPA04004948A/es active IP Right Grant
- 2002-11-25 JP JP2003546965A patent/JP4458240B2/ja not_active Expired - Lifetime
- 2002-11-25 NZ NZ533029A patent/NZ533029A/en not_active IP Right Cessation
- 2002-11-25 KR KR1020107019474A patent/KR20100102745A/ko not_active Application Discontinuation
- 2002-11-25 KR KR10-2004-7007931A patent/KR20040054803A/ko active IP Right Grant
- 2002-11-25 EA EA200400712A patent/EA007594B1/ru not_active IP Right Cessation
- 2002-11-25 EP EP02791318A patent/EP1455858A4/en not_active Withdrawn
- 2002-11-25 ME MEP-2008-80A patent/ME00015B/me unknown
- 2002-11-25 HU HU0600436A patent/HUP0600436A3/hu unknown
- 2002-11-25 IL IL16208302A patent/IL162083A0/xx unknown
- 2002-11-25 BR BR0215098-0A patent/BR0215098A/pt not_active IP Right Cessation
- 2002-11-25 CA CA2467645A patent/CA2467645C/en not_active Expired - Lifetime
- 2002-11-25 WO PCT/US2002/037878 patent/WO2003045466A2/en active Application Filing
- 2002-11-25 US US10/304,666 patent/US20030206906A1/en not_active Abandoned
- 2002-11-25 PL PL02371760A patent/PL371760A1/xx unknown
- 2002-11-25 CN CNB028275578A patent/CN100478027C/zh not_active Expired - Fee Related
- 2002-11-25 RS YU46204A patent/RS46204A/sr unknown
- 2002-11-26 AR ARP020104542A patent/AR037437A1/es unknown
- 2002-11-26 MY MYPI20024411A patent/MY140404A/en unknown
- 2002-11-26 UY UY27550A patent/UY27550A1/es not_active Application Discontinuation
- 2002-11-26 TW TW091134325A patent/TWI262794B/zh not_active IP Right Cessation
2004
- 2004-05-20 IL IL162083A patent/IL162083A/en not_active IP Right Cessation
- 2004-05-21 IS IS7275A patent/IS7275A/is unknown
- 2004-05-24 ZA ZA2004/04024A patent/ZA200404024B/en unknown
- 2004-05-26 EC EC2004005123F patent/ECSDI045123S/es unknown
- 2004-05-26 EC EC2004005123A patent/ECSP045123A/es unknown
- 2004-06-03 CO CO04052140A patent/CO5580795A2/es not_active Application Discontinuation
- 2004-06-04 HR HRP20040502 patent/HRP20040502A2/hr not_active Application Discontinuation
- 2004-06-25 NO NO20042693A patent/NO331700B1/no not_active IP Right Cessation
2006
- 2006-06-23 US US11/426,263 patent/US7829082B2/en not_active Expired - Lifetime
- 2006-06-23 US US11/426,283 patent/US20060257390A1/en not_active Abandoned
2008
- 2008-07-15 AU AU2008203131A patent/AU2008203131A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2005510302A (ja)	2005-04-21
IL162083A0 (en)	2005-11-20
MEP8008A (xx)	2010-02-10
AR037437A1 (es)	2004-11-10
CO5580795A2 (es)	2005-11-30
ECSDI045123S (xx)	2004-07-23
TW200303743A (en)	2003-09-16
AU2008203131A1 (en)	2008-08-07
WO2003045466A2 (en)	2003-06-05
MY140404A (en)	2009-12-31
CN1617738A (zh)	2005-05-18
AU2002365408B2 (en)	2008-04-24
CA2467645A1 (en)	2003-06-05
KR20040054803A (ko)	2004-06-25
EP1455858A2 (en)	2004-09-15
NO20042693L (no)	2004-08-25
EA007594B1 (ru)	2006-12-29
KR20100102745A (ko)	2010-09-24
HUP0600436A2 (en)	2006-09-28
EP1455858A4 (en)	2006-02-15
US20060246050A1 (en)	2006-11-02
ZA200404024B (en)	2005-07-27
WO2003045466A3 (en)	2003-10-09
JP4458240B2 (ja)	2010-04-28
CN100478027C (zh)	2009-04-15
UY27550A1 (es)	2003-06-30
PL371760A1 (en)	2005-06-27
ME00015B (me)	2010-06-10
HUP0600436A3 (en)	2010-12-28
ECSP045123A (es)	2004-07-23
EA200400712A1 (ru)	2005-06-30
RS46204A (xx)	2006-10-27
TWI262794B (en)	2006-10-01
NZ533029A (en)	2006-05-26
UA81235C2 (en)	2007-12-25
MXPA04004948A (es)	2004-08-11
IL162083A (en)	2012-12-31
NO331700B1 (no)	2012-02-27
IS7275A (is)	2004-05-21
US20060257390A1 (en)	2006-11-16
US7829082B2 (en)	2010-11-09
BR0215098A (pt)	2004-12-14
US20030206906A1 (en)	2003-11-06
AU2002365408A1 (en)	2003-06-10
CA2467645C (en)	2017-01-17

Publication	Publication Date	Title
US7829082B2 (en)	2010-11-09	Catheter composition and uses thereof
EP2440261B1 (en)	2016-08-24	A catheter locking solution having antimicrobial and anticoagulation properties
US6187768B1 (en)	2001-02-13	Kit for flushing medical devices and method of preparation
RU2734929C2 (ru)	2020-10-26	Раствор замка катетера и терапия с применением замка катетера
Kingston et al.	1986	Self-disinfecting plastics for intravenous catheters and prosthetic inserts
Bergeron et al.	1981	Continuous vs. intermittent administration of antimicrobial agents: tissue penetration and efficacy in vivo
US8916148B2 (en)	2014-12-23	Tissue plasminogen activator variant uses
US20070281891A1 (en)	2007-12-06	Lock solution for medical devices
Maloney et al.	2023	Nitric Oxide-Releasing Hemodialysis Catheter Lock Solutions
EP3426313B1 (en)	2021-07-07	Broad spectrum antimicrobial&anticoagulant composition
US20230015541A1 (en)	2023-01-19	16% Sodium Citrate Solution for Use as an Antimicrobial Catheter Lock Solution
Weck et al.	2005	Alteplase as a catheter locking solution: in vitro evaluation of biochemical stability and antimicrobial properties
RU2783927C2 (ru)	2022-11-22	Раствор замка катетера и терапия с применением замка катетера
Krishnakumar	2020	Physicochemical compatibility and stability of 4% sodium citrate and ethanol when stored in silicone coated and non-silicone coated glass containers
AU2023225210A1 (en)	2024-08-15	Antimicrobial solutions comprising tetrasodium edta, ethanol, and chlorhexidine and disinfecting wipes comprising said solutions
福島修司 et al.	1987	Pharmacokinetic studies of cefoperazone after bolus injection in patients with benign prostatic hypertrophy.

Legal Events

Date	Code	Title	Description
2004-12-31	A1OB	Publication of a patent application
2005-06-29	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2014-10-21	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20141021 Year of fee payment: 13
2016-05-31	OBST	Application withdrawn